Advancing the Frontier of Live Biotherapeutics: Clostridium sporogenes Research Service
Welcome to the forefront of microbiome innovation. As a leading Contract Research Organization (CRO) specializing in preclinical Live Biotherapeutic Products (LBPs), Creative Biolabs is dedicated to unlocking the therapeutic potential of the human gut microbiota. Among the most promising candidates in our portfolio is Clostridium sporogenes—a commensal bacterium with extraordinary metabolic capabilities that are reshaping our approach to neurological, oncological, and metabolic health.
Overview: The Power of Clostridium sporogenes
Clostridium sporogenes is a gram-positive, anaerobic, spore-forming bacterium. While often associated in a clinical context with its close relative C. botulinum, C. sporogenes is non-pathogenic and lacks the botulinum neurotoxin. In the realm of the microbiome, it is increasingly recognized as a "metabolic factory" within the human gut.
The primary interest in C. sporogenes stems from its unique ability to metabolize aromatic amino acids—specifically tryptophan—into potent bioactive metabolites like indole-3-propionic acid (IPA). IPA is a powerful antioxidant and a ligand for the pregnane X receptor (PXR), playing a critical role in maintaining intestinal barrier integrity and modulating systemic inflammation.
Why Research This Strain?
High Survivability: Its spore-forming nature makes it resilient during manufacturing and transit through the gastric environment.
Systemic Impact: Its metabolites can cross the blood-brain barrier, making it a key player in the "Gut-Brain Axis."
Genetic Tractability: Recent breakthroughs in gene editing technology has made C. sporogenes an ideal chassis for synthetic biology.
Our Preclinical Research Services
Navigating the complexities of anaerobic microbiology and LBP regulation requires specialized expertise. Our CRO provides a comprehensive suite of services tailored to Clostridium sporogenes development.
Analytical and Microbiological Services
Strain Characterization: Full genomic sequencing (WGS), phenotypic profiling, and metabolic flux analysis to quantify IPA production.
Custom Genetic Engineering: Utilizing advanced gene-editing tools to create "Smart C. sporogenes" strains for targeted protein secretion or prodrug conversion.
We offer a range of validated animal models to test your C. sporogenes-based therapeutic:
Germ-Free (GF) and Gnotobiotic Models: Evaluating the colonization resistance and metabolic output of the strain in a controlled microbial environment.
Disease-Specific Models: Including DSS-induced colitis, 5xFAD Alzheimer's models, and various syngeneic tumor models for oncology research.
Clostridium sporogenes Spore Suspensions is a calibrated bacterial spore suspension suitable for direct inoculation of products or selection of substrates to monitor sterilization processes.
Clostridium sporogenes Spore Suspensions is a calibrated bacterial spore suspension suitable for direct inoculation of products or selection of substrates to monitor sterilization processes.
Clostridium sporogenes Spore Suspensions is a calibrated bacterial spore suspension suitable for direct inoculation of products or selection of substrates to monitor sterilization processes.
Each instant-dissolve Clostridium sporogenes pellet is designed to deliver 10^3-10^4 CFU per 0.1 mL and provides 6 hours of stability after rehydration.
Each instant-dissolve Clostridium sporogenes pellet is designed to deliver 10^6-10^7 CFU per 0.1 mL and provides 6 hours of stability after rehydration.
Clostridium sporogenes DNA Standard product can be used for quantitative research and analysis, assay development, verification, and validation, and laboratory quality control.
This product contains high-quality, intact genomic DNA isolated from Clostridium sporogenes Genomic DNA. It is a purified and ready-to-use DNA sample, ideal for a wide range of molecular biology applications, including PCR, qPCR, and Next-Generation Sequencing.
Research Applications: Disease Targeting and Efficacy
Current research into Clostridium sporogenes is expanding rapidly across several therapeutic areas. As a CRO, we support investigators in validating these applications through rigorous preclinical models.
The most compelling application of C. sporogenes lies in its production of IPA. Low levels of circulating IPA have been linked to cognitive decline.
Alzheimer's and Parkinson's: Research indicates that C. sporogenes-derived IPA protects neurons from oxidative stress and inhibits the formation of amyloid-beta fibrils.
Multiple Sclerosis (MS): By activating PXR and reducing neuroinflammation, this strain shows promise in limiting demyelination in EAE (Experimental Autoimmune Encephalomyelitis) models.
C. sporogenes possesses a unique "hypoxia-targeting" ability. Because it is an obligate anaerobe, it can selectively colonize the necrotic, oxygen-depleted cores of solid tumors—areas that are typically resistant to chemotherapy and radiation. Researchers are engineering C. sporogenes to express enzymes that convert non-toxic prodrugs into active cytotoxic agents directly inside the tumor, minimizing systemic side effects.
Type 2 Diabetes: IPA has been shown to improve insulin sensitivity and glucose homeostasis.
IBD and Leaky Gut: By strengthening tight junction proteins via PXR activation, C. sporogenes helps restore the mucosal barrier in models of ulcerative colitis and Crohn's disease.
Why Partner With Us?
Choosing the right CRO is the most critical decision in your preclinical journey. Our company stands out through:
Deep Expertise in Anaerobes
We understand the "Oxygen Problem." Our labs are equipped with state-of-the-art anaerobic chambers and bioreactors specifically designed for Clostridia.
Regulatory Readiness
Our data packages are built with IND (Investigational New Drug) submissions in mind, adhering to the highest standards of data integrity.
Integrated Platform
We offer an end-to-step solution-from genetic design and in vitro screening to complex in vivo disease models.
Proprietary Spore Technology
Our unique stabilization methods ensure that your LBP remains viable and potent through manufacturing and administration.
A New Era of Microbiome Medicine
The transition of Clostridium sporogenes from a common soil and gut dweller to a high-tech therapeutic vehicle represents a significant milestone in microbiome science. Whether it is through the systemic benefits of its metabolites in treating neurodegeneration or its unique ability to infiltrate and destroy tumors from within, this strain holds the key to solving some of modern medicine's toughest challenges.
At Creative Biolabs, we don't just provide data; we provide a partnership. We believe that Live Biotherapeutics is the future of personalized medicine, offering a level of safety and specificity that traditional chemistry cannot match. By combining your innovative vision with our specialized preclinical infrastructure, we can accelerate the journey from the laboratory bench to the patient's bedside.
In its wild-type form, it is a common inhabitant of the human gut. For therapeutic use, it is classified as a Live Biotherapeutic Product (LBP). Preclinical safety assessments, including antibiotic susceptibility testing and toxin gene screening, are standard parts of our service.
How do you measure the "potency" of a C. sporogenes candidate?
Potency is usually measured by a combination of viable spore count (CFU/mL) and the concentration of indole-3-propionic acid (IPA) produced under standardized fermentation conditions.
Can you help with the genetic modification of the strain?
Yes. We have a dedicated synthetic biology team experienced in Clostridial gene editing, including gene knockouts and the insertion of therapeutic payloads.
Online Inquiry
For Research Use Only. Not intended for use in
food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
